Võrdle meetodeid

	EORTC QLQ-C30	Fibromüalgia mõju küsimustik
Valdkond	Tervisetulemid	Tervisetulemid
Perekond	Process / pipeline	Process / pipeline
Tekkeaasta	1993	1991
Looja	Nico Aaronson et al.	Cynthia S. Burckhardt et al.
Tüüp	Self-report quality of life questionnaire	Self-report symptom and functional impairment questionnaire
Algallikas	Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., ... & Takeda, F. (1993). The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365-376.	Burckhardt, C. S., Clark, S. R., & Bennett, R. M. (1991). The Fibromyalgia Impact Questionnaire: Development and validation. The Journal of Rheumatic Diseases, 18(5), 728-735.
Rööpnimetused	QLQ-C30, EORTC QLQ-C30, Cancer Quality of Life Scale	FIQ, Fibromyalgia Impact, Fibromyalgia Questionnaire
Seotud	5	4
Kokkuvõte	The EORTC QLQ-C30 is the most widely used international instrument for assessing quality of life in cancer patients. Developed by the European Organisation for Research and Treatment of Cancer in 1993, it measures physical, emotional, cognitive, and social functioning alongside cancer-specific symptoms and financial impact, making it the standard outcome measure in oncology clinical trials and patient care.	The FIQ is the most widely used patient-reported outcome measure for fibromyalgia disease burden. Developed by Cynthia Burckhardt and colleagues in 1991, this 10-item questionnaire quantifies how fibromyalgia affects physical function, work capacity, depression, anxiety, sleep, pain, and fatigue. The revised version (FIQR, 21 items) offers enhanced psychometric properties and is the current standard in fibromyalgia clinical trials and practice.